Nanotherapeutics gets $30.9 mn NIAID contract to develop inhaled antiviral for prophylaxis & treatment of smallpox

Nanotherapeutics, Inc, has been awarded a $30.9 million, five-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major). 

Comments

Popular posts from this blog

Trump wants more mental health care; Alabama says it's trying

Smokefree Mumbai campaign responds to recent study by BCM, Houston that claims smoking create stronger memory